<p>Expected proportion of correctly classified women, expected costs and incremental cost per correctly classified woman for all test strategies in the main analysis and the two univariate sensitivity analyses excluding strategies containing a dipslide and strategies containing a sediment.</p
<p>Incremental cost-effectiveness ratio (ICER) of screening optimized to a pre-vaccination cohort as...
Univariate and multivariate analysis of overall survival and cancer-specific survival in women.</p
<p>These are calculated both with and without considering costs (see text). When costs are considere...
Outcomes and costs as increments per strategy vs. no screening, mean (confidence interval) per woman...
<p>Strategies for adding genetic testing and yield of reclassification in terms of fraction of women...
<p>Distribution of ordered results from 10,000 model runs with input parameters varying randomly acc...
Results of a univariate sensitivity analysis of key variables on cost per DALY averted.</p
<p>Univariable analysis (odds ratios) of all symptoms in women and men separately.</p
<p>Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-t...
<p>Results of sensitivity analysis on mean cost of care per woman treated in 2012$.</p
<p>Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-t...
<p>*OR, odds ratio; CI, confidence interval, SD (standard deviation)</p><p>Univariate analysis asses...
<p>Scenario probabilities for the percentage of women who are accessing PMTCT at each stage in the m...
Multivariate analyses of increasing, stable, biphasic and decreasing symptom prevalence in women.</p
a<p>95% confidence intervals (CIs) based on probabilistic sensitivity analysis using baseline statis...
<p>Incremental cost-effectiveness ratio (ICER) of screening optimized to a pre-vaccination cohort as...
Univariate and multivariate analysis of overall survival and cancer-specific survival in women.</p
<p>These are calculated both with and without considering costs (see text). When costs are considere...
Outcomes and costs as increments per strategy vs. no screening, mean (confidence interval) per woman...
<p>Strategies for adding genetic testing and yield of reclassification in terms of fraction of women...
<p>Distribution of ordered results from 10,000 model runs with input parameters varying randomly acc...
Results of a univariate sensitivity analysis of key variables on cost per DALY averted.</p
<p>Univariable analysis (odds ratios) of all symptoms in women and men separately.</p
<p>Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-t...
<p>Results of sensitivity analysis on mean cost of care per woman treated in 2012$.</p
<p>Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-t...
<p>*OR, odds ratio; CI, confidence interval, SD (standard deviation)</p><p>Univariate analysis asses...
<p>Scenario probabilities for the percentage of women who are accessing PMTCT at each stage in the m...
Multivariate analyses of increasing, stable, biphasic and decreasing symptom prevalence in women.</p
a<p>95% confidence intervals (CIs) based on probabilistic sensitivity analysis using baseline statis...
<p>Incremental cost-effectiveness ratio (ICER) of screening optimized to a pre-vaccination cohort as...
Univariate and multivariate analysis of overall survival and cancer-specific survival in women.</p
<p>These are calculated both with and without considering costs (see text). When costs are considere...